FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market
Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Battery innovation is going gangbusters, driven by environmental and social imprimaturs, leading experts to conclude that it is not a matter of if but when lithium will be dethroned – prepare for the great reshuffle
A glance through the latest expert views and predictions about commodities: Nuanced policy support in China; base metals/energy transition metals versus bulks; lows are in for aluminium in 2023 & the outlook for gold
Research reports on ASX-listed companies, to download in full
A miss on the Q4 gross margin and Eli Lilly targeting the CPAP market have kept ResMed shares under selling pressure since Friday last week
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
